Search in:

Advanced search

Expert Review of Pharmacoeconomics & Outcomes Research Volume 14, 2014 - Issue 1

Submit an article Journal homepage

280

Views

CrossRef citations to date

Altmetric

Reviews

Trends and issues in oncology costs

Julieta F ScaloHealth Outcomes and Pharmacy Practice Division, The University of Texas at Austin, College of Pharmacy, 1 University Station A1900, Austin, TX 78712, USACorrespondence[email protected]

Karen L RascatiHealth Outcomes and Pharmacy Practice Division, The University of Texas at Austin, College of Pharmacy, 1 University Station A1900, Austin, TX 78712, USA

Pages 35-44 | Published online: 13 Dec 2013

Cite this article
https://doi.org/10.1586/14737167.2014.864561
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

References

Keehan SP, Sisko AM, Truffer CJ et al. National health spending projections through 2020: economic recovery and reform drive faster spending growth. Health Aff. 30(8), 1594–1605 (2011).
PubMed Web of Science ®Google Scholar
Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J. Natl Cancer Inst. 103(2), 117–128 (2011).
PubMed Web of Science ®Google Scholar
IOM (Institute of Medicine). Delivering high-quality cancer care: charting a new course for a system in crisis. The National Academies Press, Washington, DC, USA.
Google Scholar
Tangka FK, Trogdon JG, Richardson LC, Howard D, Sabatino SA, Finkelstein EA. Cancer treatment cost in the United States: has the burden shifted over time? Cancer 116(14), 3477–3484 (2010).
PubMed Web of Science ®Google Scholar
Short PF, Moran JR, Punekar R. Medical expenditures of adult cancer survivors aged <65 years in the United States. Cancer 117(12), 2791–2800 (2011).
PubMed Web of Science ®Google Scholar
Bodenheimer T, Berenson R. The primary care–specialty income gap: why it matters. Ann. Intern. Med. 146(4), 301–306 (2007).
PubMedGoogle Scholar
Twombly R. Medicare cost containment strategy targets several oncology drugs. J. Natl Cancer Inst. 96(17), 1268–1270 (2004).
PubMedGoogle Scholar
Benson LR. Reimbursing cancer care: Medicare policies challenged. J. Natl Cancer Inst. 93(21), 1595–1597 (2001).
PubMedGoogle Scholar
Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. J. Natl Cancer Inst. 100(12), 888–897 (2008).
PubMedGoogle Scholar
Schrag D. The price tag on progress – chemotherapy for colorectal cancer. N. Engl. J. Med. 351(4), 317–319 (2004).
PubMed Web of Science ®Google Scholar
Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J. Clin. Oncol. 25(2), 180–186 (2007).
PubMed Web of Science ®Google Scholar
Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl Cancer Inst. 101(15), 1044–1048 (2009).
PubMedGoogle Scholar
Smith TJ, Hillner BE. Concrete options and ideas for increasing value in oncology care: the view from one trench. Oncologist 15( Suppl. 1), 65–72 (2010).
PubMedGoogle Scholar
Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J. Clin. Oncol. 27(13), 2111–2113 (2009).
PubMed Web of Science ®Google Scholar
Doloresco F, Fominaya C, Schumock G. Projecting future drug expenditures – 2011. Am. J. Health Syst. Pharm. 68, e1–e12 (2011).
Google Scholar
Hoffman JM, Li E, Doloresco F et al. Projecting future drug expenditures – 2012. Am. J. Health Syst. Pharm. 69(5), 405–421 (2012).
PubMedGoogle Scholar
Aitken M, Kleinrock M. Declining Medicine Use and Costs: for Better or Worse? IMS Institute for Healthcare Informatics, Parsippany, NJ, USA.
Google Scholar
Hoffman JM, Li E, Doloresco F et al. Projecting future drug expenditures in US nonfederal hospitals and clinics – 2013. Am. J. Health Syst. Pharm. 70, 525–539 (2013).
PubMedGoogle Scholar
Chambers JD, Neumann PJ. Listening to Provenge – what a costly cancer treatment says about future Medicare policy. N. Engl. J. Med. 364(18), 1687–1689 (2011).
PubMed Web of Science ®Google Scholar
Sledge GW. Musings of a cancer doctor: the cost of drugs. Oncol. Times 33(16), 32 (2011).
Google Scholar
Ginsburg G, Konstance R, Allsbrook J, Schulman K. Implications of pharmacogenomics for drug development and clinical practice. Arch. Intern. Med. 165(20), 2331–2336 (2005).
PubMed Web of Science ®Google Scholar
Gavel S. The oncology pipeline: maturing, competitive, and growing? Oncol. Bus. Rev. 14–16 (2008).
Google Scholar
Conti RM, Bernstein AC, Villaflor VM, Schilsky RL, Rosenthal MB, Bach PB. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J. Clin. Oncol. 31(9), 1134–1139 (2013).
PubMed Web of Science ®Google Scholar
Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011. CA Cancer J. Clin. 61, 212–236 (2009).
Google Scholar
Silberman G, Downs CG. Recent legislation changes the economics of cancer care. ONS News 20(7), 9 (2005).
PubMedGoogle Scholar
Iglehart J. Medicare and drug pricing. N. Engl. J. Med. 348(16), 1590–1597 (2003).
PubMed Web of Science ®Google Scholar
Bailes JS, Coleman T. The new Medicare bill: far-reaching effects on cancer treatment. Clin. Adv. Hematol. Oncol. 2(5), 292–294 (2004).
PubMedGoogle Scholar
Potetz L, DeWilde LF. Cancer and Medicare: A Chartbook. American Cancer Society Cancer Action Network, Washington, DC, USA.
Google Scholar
Malin JL, Weeks JC, Potosky AL, Hornbrook MC, Keating NL. Medical oncologists‘ perceptions of financial incentives in cancer care. J. Clin. Oncol. 31(5), 530–535 (2013).
PubMed Web of Science ®Google Scholar
Jacobson M, O‘Malley AJ, Earle CC, Pakes J, Gaccione P, Newhouse JP. Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff. 25(2), 437–443 (2006).
Google Scholar
Shahinian VB, Kuo Y-F, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 363(19), 1822–1832 (2010).
PubMedGoogle Scholar
Jacobson M, Earle CC, Price M, Newhouse JP. How medicare‘s payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health Aff. 29(7), 1391–1399 (2010).
Google Scholar
Grumbach K, Osmond D, Vranizan K. Primary care physicians‘ experience of financial incentives in managed-care systems. N. Engl. J. Med. 339(21), 1516–1521 (1998).
PubMedGoogle Scholar
McGivney WT, Mullen J. Cancer and managed care in the 21st century. Am. J. Manag. Care 11( 17 Suppl.), S509–S521 (2005).
Google Scholar
Timmermans S, Mauck A. The promises and pitfalls of evidence-based medicine. Health Aff. 24(1), 18–28 (2005).
PubMed Web of Science ®Google Scholar
Draper D, Hurley R, Lesser C, Strunk B. The changing face of managed care. Health Aff. 21(1), 11–23 (2002).
Google Scholar
Garber AM. Evidence-based guidelines as a foundation for performance incentives. Health Aff. 24(1), 174–179 (2005).
Web of Science ®Google Scholar
Danielson E, Demartino J, Mullen JA. Managed care & medical oncology: the focus is on value. J. Natl Compr. Canc. Netw. 8 ( Suppl. 7), S28–S37 (2010).
Google Scholar
Dunn JD, Ellis PG, Fox JL et al. Payer and provider collaborations that improve quality outcomes in oncology. Manag. Care. 19(11), 35–40, 42 (2010).
PubMedGoogle Scholar
Neubauer MA, Hoverman JR, Kolodziej M et al. Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. J. Oncol. Pract. 6(1), 12–18 (2010).
PubMedGoogle Scholar
Hoverman JR, Cartwright TH, Patt DA et al. Pathways, outcomes, and costs in colon cancer: retrospective evaluations in two distinct databases. J. Oncol. Pract. 7(3S), 52s–59s (2011).
Google Scholar
Eichler H-G, Abadie E, Breckenridge A et al. Bridging the efficacy–effectiveness gap: a regulator‘s perspective on addressing variability of drug response. Nat. Rev. Drug Discov. 10(7), 495–506 (2011).
PubMed Web of Science ®Google Scholar
Newcomer L. Cost of new oncology drugs. Clin. Adv. Hematol. Oncol. 8(5), 313–314 (2010).
PubMedGoogle Scholar
Holcombe D. Oncology management programs for payers and physicians: evaluating current models and diagnosing successful strategies for payers and physicians. J. Oncol. Pract. 7(3 Suppl.), e46s–e49s (2011).
PubMedGoogle Scholar
Blackmore CC, Mecklenburg RS, Kaplan GS. At Virginia Mason, collaboration among providers, employers, and health plans to transform care cut costs and improved quality. Health Aff. 30(9), 1680–1687 (2011).
Web of Science ®Google Scholar
Regan M. Cancer and disease management: indications for action. Dis. Manag. Health Out. 6(4), 203–211 (1999).
Google Scholar
Ellrodt G, Cook DJ, Lee J, Cho M, Hunt D, Weingarten S. Evidence-based disease management. JAMA 278(20), 1687–1692 (1997).
PubMedGoogle Scholar
Hunter DJ, Fairfield G. Managed care: disease management. BMJ 315(7099), 50–53 (1997).
PubMedGoogle Scholar
Villagra V. Strategies to control costs and quality: a focus on outcomes research for disease management. Med. Care 42(4), 24–30 (2004).
Google Scholar
Kash KM, Sharma S, Goldfarb NI. Is disease management right for oncology? Popul. Health Manag. 12(6), 337–343 (2009).
PubMedGoogle Scholar
Pierce D. Managing managed care. Oncology Issues November/December, 32–35 (2005).
Google Scholar
Fetterolf DE, Terry R. Oncology disease management. Dis. Manag. 10(1), 30–36 (2007).
PubMedGoogle Scholar
Eijkenaar F. Key issues in the design of pay for performance programs. Eur. J. Health Econ. 14(1), 117–131 (2013).
PubMedGoogle Scholar
Chen JY, Kang N, Juarez DT, Hodges KA, Chung RS. Impact of a pay-for-performance program on low performing physicians. J. Healthc. Qual. 32(1), 13–22 (2010).
PubMedGoogle Scholar
Rosenthal M, Landon B. Pay for performance in commercial HMOs. N. Engl. J. Med. 355(18), 1895–1902 (2006).
PubMed Web of Science ®Google Scholar
Hahn J, Morgan P, Stockdale H, Stone J. Medicare Provisions in PPACA (PL 111–148). Congressional Research Service.
Google Scholar
Rosenthal MB, Landon BE, Howitt K, Song HR, Epstein AM. Climbing up the pay-for-performance learning curve: where are the early adopters now? Health Aff. 26(6), 1674–1682 (2007).
Web of Science ®Google Scholar
Siegel RD, Clauser SB, Lynn JM. National Collaborative to Improve Oncology Practice: The National Cancer Institute Community Cancer Centers Program Quality Oncology Practice Initiative Experience. J. Oncol. Pract. 5(6), 276–281 (2009).
PubMedGoogle Scholar
National Cancer Policy Board. Ensuring Quality Cancer Care. National Academy Press. Washington, DC, USA (1999).
Google Scholar
Desch CE, McNiff KK, Schneider EC et al. American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J. Clin. Oncol. 26(21), 3631–3637 (2008).
PubMed Web of Science ®Google Scholar
Newcomer LN, Perkins MR, Donelan SA. Tying payment incentives to quality measurement. J. Oncol. Pract. 9(3), 119–121 (2013).
PubMedGoogle Scholar
Chamie K, Saigal CS, Lai J et al. Quality of care in patients with bladder cancer. Cancer 118(5), 1412–1421 (2012).
PubMed Web of Science ®Google Scholar
Lee TH, Bothe A, Steele GD. How Geisinger structures its physicians‘ compensation to support improvements in quality, efficiency, and volume. Health Aff. 31(9), 2068–2073 (2012).
Google Scholar
Mechanic RE. Opportunities and challenges for episode-based payment. N. Engl. J. Med. 365(9), 777–779 (2011).
PubMedGoogle Scholar
Stange KC, Nutting PA, Miller WL et al. Defining and measuring the patient-centered medical home. J. Gen. Intern. Med. 25(6), 601–612 (2010).
PubMed Web of Science ®Google Scholar
McClellan M, McKethan AN, Lewis JL, Roski J, Fisher ES. A national strategy to put accountable care into practice. Health Aff. 29(5), 982–990 (2010).
Web of Science ®Google Scholar
Mahan CE. Regulatory, policy and quality update for venous thromboembolism and stroke in United States hospitals. Thromb. Res. 130(4), 586–590 (2012).
PubMedGoogle Scholar
Sox HC. Comparative effectiveness research: a report from the Institute of Medicine. Ann. Intern. Med. 151(3), 203 (2009).
PubMed Web of Science ®Google Scholar
Lyman GH. Comparative effectiveness research in oncology. Oncologist 18(6), 752–759 (2013).
PubMedGoogle Scholar
Roberts TG. Preparing for success with comparative effectiveness research. Oncologist 18(6), 655–657 (2013).
PubMedGoogle Scholar
Tunis SR, Benner J, McClellan M. Comparative effectiveness research: policy context, methods development and research infrastructure. Stat. Med. 29(19), 1963–1976 (2010).
PubMed Web of Science ®Google Scholar
Miksad RA, Schnipper L, Goldstein M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J. Clin. Oncol. 25(28), 4506–4507, author reply 4508 (2007).
PubMedGoogle Scholar
Montero AJ, Avancha K, Glück S, Lopes G. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Res. Treat. 132(2), 747–751 (2012).
PubMedGoogle Scholar
Hornberger J, Reyes C, Lubeck D, Valente N. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk. Lymphoma 49(2), 227–236 (2008).
PubMed Web of Science ®Google Scholar
Garrison LP, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 110(3), 489–498 (2007).
PubMed Web of Science ®Google Scholar
Buxton MJ. Economic evaluation and decision making in the UK. Pharmacoeconomics 4(11), 1133–1142 (2006).
Google Scholar
Nadler E. Do oncologists believe new cancer drugs offer good value? Oncologist 11(2), 90–95 (2006).
PubMed Web of Science ®Google Scholar
Gold MR, Sofaer S, Siegelberg T. Medicare and cost-effectiveness analysis: time to ask the taxpayers. Health Aff. 26(5), 1399–1406 (2007).
Google Scholar
Jonsen A. Bentham in a box: technology assessment and health care allocation. L. Med Health Care 14(3–4), 172–174 (1986).
PubMedGoogle Scholar
Brock DW. Ethical and value issues in insurance coverage for cancer treatment. Oncologist 15( Suppl. 1), 36–42 (2010).
PubMedGoogle Scholar
Temel JS, Greer JA, Muzikansky A et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N. Engl. J. Med. 363(8), 733–742 (2010).
PubMed Web of Science ®Google Scholar
Mack JW, Weeks JC, Wright AA, Block SD, Prigerson HG. End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J. Clin. Oncol. 28(7), 1203–1208 (2010).
PubMed Web of Science ®Google Scholar
Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J. Clin. Oncol. 26(23), 3860–3866 (2008).
PubMed Web of Science ®Google Scholar
Peppercorn JM, Smith TJ, Helft PR et al. American Society of Clinical Oncology statement: toward individualized care for patients with advanced cancer. J. Clin. Oncol. 29(6), 755–760 (2011).
PubMed Web of Science ®Google Scholar
Levy MH, Back A, Benedetti C et al. NCCN clinical practice guidelines in oncology: palliative care. J. Natl Compr. Canc. Netw. 7(4), 436–473 (2009).
PubMedGoogle Scholar
Smith TJ, Hillner BE. Bending the cost curve in cancer care. N. Engl. J. Med. 364(21), 2060–2065 (2011).
PubMed Web of Science ®Google Scholar
Neumann PJ, Palmer JA, Nadler E, Fang C, Ubel PA. Cancer therapy costs influence treatment: a national survey of oncologists. Health Aff. 29(1), 196–202 (2010).
PubMed Web of Science ®Google Scholar
Meropol NJ, Schrag D, Smith TJ et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J. Clin. Oncol. 27(23), 3868–3874 (2009).
PubMed Web of Science ®Google Scholar

Websites

Cancer Trends Progress Report – 2007 Update. National Cancer Institute, NIH, DHHS, Bethesda, MD, USA (2007). http://progressreport.cancer.gov ( Accessed 13 September 2013)
Google Scholar
Cancer Trends Progress Report – 2009/2010 Update. National Cancer Institute, NIH, DHHS, Bethesda, MD, USA (2010). http://progressreport.cancer.gov ( Accessed 13 September 2013)
Google Scholar
Report to the Congress: variation and innovation in Medicare. Medicare Payment Advisory Commission, Washington, DC, USA 1–230 (2003). http://medpac.gov/documents/June03_Entire_Report.pdf ( Accessed 16 September 2013)
Google Scholar
Berenson A. A Cancer Drug‘s Big Price Rise Is Cause for Concern. The New York Times (12 March 2006). http://nytimes.com/2006/03/12/business/12price.html?pagewanted=all ( Accessed 15 September 2013)
Google Scholar
Lexi-Comp Online. 2011 ed. Lexi-Drugs Online. Hudson, OH: Lexi-Comp, Inc. http://online.lexi.com/ ( Accessed 11 September 2013)
Google Scholar
Clinton calls for Medicare crackdown. CNNcom. (1997). http://cnn.com/ALLPOLITICS/1997/12/13/clinton.radio/ ( Accessed 28 October 2013)
Google Scholar
Concerns about average wholesale price-based reimbursement raised again. Cancer Network - Home of the Journal of Oncology. (2001). http: cancernetwork.com/articles/concerns-about-average-wholesale-price-based-reimbursement-raised-again ( Accessed 18 September 2013)
Google Scholar
Medicare Part B Drugs: Program Payments Should Reflect Market Prices. U.S. General Accounting Office, Washington, DC, USA (2001). http://gao.gov/new.items/d011142t.pdf ( Accessed 14 September 2013)
Google Scholar
Medicare: Payments for Covered Outpatient Drugs Exceed Providers’ Cost. U.S. General Accounting Office, Washington, DC, USA (2001). http://gao.gov/new.items/d011118.pdf ( Accessed 14 September 2013)
Google Scholar
Jeffrey NA, Winslow R. California jury orders Aetna to pay $116 million in damages. The Wall Street Journal (21 January 1999). http://online.wsj.com/article/SB91688814591338813.html ( Accessed 9 September 2013)
Google Scholar
NCCN Guidelines & Clinical Resources. 2011 ed. The National Comprehensive Cancer Network. http://nccn.org/clinical.asp ( Accessed 28 September 2013)
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Trends and issues in oncology costs

References

Websites

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Trends and issues in oncology costs

References

Websites

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date